Notice: Educational. Affiliate links. Not medical advice.
The most complete and honest comparison of 2026. Clinical data, real cost, mechanism, and availability — side by side.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | |||
| Active receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Pharmacological class | Mono-agonist | Dual agonist | Triple agonist |
| Frequency | Once weekly | Once weekly | Once weekly (expected) |
| Clinical efficacy | |||
| Average loss (trial) | ~15% (STEP-1) | ~21% (SURMOUNT-1) | ~24% (Phase 2 NEJM) |
| Trial duration | 68 weeks | 72 weeks | 48 weeks |
| A1c reduction (diabetics) | ~1.5% | ~2.3% | ~2.0% (preliminary) |
| Regulatory & availability | |||
| FDA-approved brands | Ozempic · Wegovy · Rybelsus | Mounjaro · Zepbound | None · Pre-FDA |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Compounded available | ✓ Via 503A | ✓ Via 503A | No (illegal) |
| Cost (estimated USA) | |||
| FDA brand, no insurance | ~$1,000-$1,400/mo | ~$1,000-$1,400/mo | Pending |
| Compounded telehealth | ~$179-$349/mo | ~$249-$499/mo | Pending |
| Insurance coverage | Variable (Wegovy) | Variable (Zepbound) | Pending |
| Side effects | |||
| Nausea/GI | Common | Common | Common |
| Muscle mass loss | Risk | Risk (lower) | Risk (more studies pending) |
| Hypoglycemia | Low risk | Low risk | Low risk (preliminary) |
Sources: STEP-1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), Jastreboff et al. Phase 2 Retatrutide (NEJM 2023), FDA Drug Approval Database. Data as of 2026. Individual results vary.
No hype. Just honest logic based on your specific situation.
If you're NEW to GLP-1 and want to start TODAY
→ Compounded tirzepatide via 503A telehealth is the best balance between proven efficacy (~21% loss) and affordable cost. Semaglutide is a cheaper alternative but with less efficacy.
See recommended programs →If you're already on semaglutide and plateaued
→ Talk to your doctor about switching to tirzepatide now. Waiting for Retatrutide (12-18 months) could cost you progress. Switching medications typically reactivates loss.
If you have < 5% to lose and you're patient
→ Waiting for Retatrutide makes sense. The last few pounds are the hardest — a more potent medication can make the difference. Subscribe to the Approval Tracker.
If you need to lose > 30% of weight
→ Start with tirzepatide TODAY. Time matters more than the difference between 21% and 24% for you. When Retatrutide is approved, your doctor can evaluate transition.
If your insurance doesn't cover anything
→ Compounded telehealth via 503A is ~70-80% cheaper than the FDA brand. Make sure the program discloses its 503A pharmacy.
Evaluate the 3 programs we recommend as a clinical bridge to the Retatrutide launch.
See recommended programs →